12 hours ago
2
Soumya Eswaran
Tue, May 5, 2026 astatine 10:20 AM CDT 3 min read
Riverwater Partners, an concern absorption company, released its “Small Cap Strategy” Q1 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. In Q1 2026, the Riverwater Small Cap Strategy outperformed the Russell 2000 Index. The 4th rewarded patience and discipline. The archetypal 4th of 2026 saw a important displacement successful marketplace enactment and hazard perceptions, owed to geopolitical tensions successful the Middle East and concerns implicit sustainable maturation successful the bundle and AI sectors. Additionally, backstage recognition markets are nether stress. In this environment, the steadfast is concentrating connected identifying marketplace dislocations caused by what it perceives arsenic indiscriminate selling, peculiarly successful AI-related areas. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.
In its first-quarter 2026 capitalist letter, Riverwater Partners Small Cap Strategy highlighted stocks similar AtriCure, Inc. (NASDAQ:ATRC). AtriCure, Inc. (NASDAQ:ATRC) is simply a aesculapian instrumentality institution focused connected the improvement and manufacture of technologies for the surgical ablation of cardiac tissue, exclusion of the near atrial appendage, and impermanent symptom management. On May 4, 2026, AtriCure, Inc. (NASDAQ:ATRC) closed astatine $28.78 per share. One-month instrumentality of AtriCure, Inc. (NASDAQ:ATRC) was 0.17%, and its shares mislaid 3.05% implicit the past 52 weeks. AtriCure, Inc. (NASDAQ:ATRC) has a marketplace capitalization of $1.46 billion.
Riverwater Partners Small Cap Strategy stated the pursuing regarding AtriCure, Inc. (NASDAQ:ATRC) successful its Q1 2026 capitalist letter:
"AtriCure, Inc. (NASDAQ:ATRC) underperformed during the archetypal 4th of 2026 contempt delivering a beardown net study and providing 2026 guidance that came successful supra thoroughfare expectations, reflecting continued momentum crossed its halfway atrial fibrillation and appendage absorption businesses. The stock’s weakness was driven little by fundamentals and much by a displacement successful capitalist sentiment pursuing Edwards Lifesciences’ announcement of a competing surgical near atrial appendage closure (LAAC) product, which volition straight vie with AtriCure’s AtriClip franchise. This improvement created an overhang connected the shares, arsenic investors reassessed the durability of AtriCure’s marketplace enactment successful appendage management. However, Edwards’ merchandise is not expected to beryllium afloat disposable until precocious successful 2026 oregon 2027, portion AtriCure’s AtriClip is already good established and wide adopted among cardiac surgeons, supported by beardown objective information and entrenched doc relationships. In our view, the sell-off reflects near-term competitory concerns alternatively than a deterioration successful the company’s underlying maturation trajectory, and AtriCure remains good positioned fixed its first-mover vantage and heavy integration wrong surgical workflows."
English (CA) · 
English (US) · 
Spanish (MX) ·